“Affirm’s Q1 Success Pushes Shares Up 9%; Full-Year Forecast Upgraded”
Affirm Holdings Inc. surpassed analysts' expectations with strong Q1 fiscal 2026 results, triggering a 9% surge in shares. This growth reflects a robust financial performance, including a 42% rise in Gross Merchandise Volume and increase in active consumers. Despite a conservative Q2 forecast, Affirm's raised full-year guidance signals continued profitability and market strength. Read more
Read More
“RBC Capital’s Price Target Boosts Outlook for Viridian Therapeutics (NASDAQ:VRDN)”
Discover RBC Capital's bullish outlook on Viridian Therapeutics (VRDN), predicting a potential 63.64% increase in its stock price, driven by strategic initiatives and positive financial positioning. Amid reduced competition from Roche's Enspryng, find out how Viridian emerges as a promising player in the biotech sector. Read more
Read More
“Significant Rise in IREN Limited’s Consensus Price Target”
Analysts showcase bullish sentiment towards NASDAQ: IREN, raising its average price target to $78.50 amid positive financial projections. IREN Limited, a stalwart in Bitcoin mining, benefits from a significant Microsoft AI Cloud contract. Despite increased confidence in IREN's robust business model, investors should consider potential risks and monitor latest financial updates. Read more
Read More